Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B.

Le Bert N, Salimzadeh L, Gill US, Dutertre CA, Facchetti F, Tan A, Hung M, Novikov N, Lampertico P, Fletcher SP, Kennedy PTF, Bertoletti A.

J Hepatol. 2019 Jul 23. pii: S0168-8278(19)30424-6. doi: 10.1016/j.jhep.2019.07.015. [Epub ahead of print]

PMID:
31348999
2.

Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.

Akbar SM, Chen S, Al-Mahtab M, Abe M, Hiasa Y, Onji M.

Antiviral Res. 2012 Oct;96(1):59-64. doi: 10.1016/j.antiviral.2012.07.011. Epub 2012 Aug 1.

PMID:
22884884
3.

[The characteristic of T cells response to HBV-specific antigen proteins in patients with HBV infection].

Feng X, Yan HP, Liao HY, Liu YM, Zhang GY, Lin F, Zhao Y, Huang YL.

Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2012 Aug;26(4):253-5. Chinese.

PMID:
23189836
4.

Decades after recovery from hepatitis B and HBsAg clearance the CD8+ T cell response against HBV core is nearly undetectable.

Kefalakes H, Jochum C, Hilgard G, Kahraman A, Bohrer AM, El Hindy N, Heinemann FM, Verheyen J, Gerken G, Roggendorf M, Timm J.

J Hepatol. 2015 Jul;63(1):13-9. doi: 10.1016/j.jhep.2015.01.030. Epub 2015 Jan 31.

PMID:
25646888
5.

HBsAg, HBcAg, and combined HBsAg/HBcAg-based therapeutic vaccines in treating chronic hepatitis B virus infection.

Akbar SM, Al-Mahtab M, Uddin MH, Khan MS.

Hepatobiliary Pancreat Dis Int. 2013 Aug;12(4):363-9. Review.

PMID:
23924493
6.

[Expression and clinical significance of HBsAg and HBcAg in hepatocytes in chronic hepatitis B].

Wang GS, Wang MM, Xie QL, Ming L, Jiang XN, Chen LW, Liu MH.

Zhonghua Gan Zang Bing Za Zhi. 2004 May;12(5):287-9. Chinese.

PMID:
15161505
7.

Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.

Li J, Ge J, Ren S, Zhou T, Sun Y, Sun H, Gu Y, Huang H, Xu Z, Chen X, Xu X, Zhuang X, Song C, Jia F, Xu A, Yin X, Du SX.

Vaccine. 2015 Aug 20;33(35):4247-54. doi: 10.1016/j.vaccine.2015.03.079. Epub 2015 Apr 6.

PMID:
25858855
8.

Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice.

Dai S, Zhuo M, Song L, Chen X, Yu Y, Zang G, Tang Z.

Immunobiology. 2016 Jul;221(7):813-21. doi: 10.1016/j.imbio.2016.01.015. Epub 2016 Feb 2.

PMID:
26874581
9.

Hepatitis B virus core and e antigen: immune recognition and use as a vaccine carrier moiety.

Schödel F, Peterson D, Milich D.

Intervirology. 1996;39(1-2):104-10.

PMID:
8957676
10.

Therapeutic potential of a combined hepatitis B virus surface and core antigen vaccine in patients with chronic hepatitis B.

Al-Mahtab M, Akbar SM, Aguilar JC, Uddin MH, Khan MS, Rahman S.

Hepatol Int. 2013 Oct;7(4):981-9. doi: 10.1007/s12072-013-9486-4. Epub 2013 Nov 9.

PMID:
26202028
11.

The hepatitis B virus core and e antigens elicit different Th cell subsets: antigen structure can affect Th cell phenotype.

Milich DR, Schödel F, Hughes JL, Jones JE, Peterson DL.

J Virol. 1997 Mar;71(3):2192-201.

12.

DNA immunization with fusion of CTLA-4 to hepatitis B virus (HBV) core protein enhanced Th2 type responses and cleared HBV with an accelerated kinetic.

Yin Y, Wu C, Song J, Wang J, Zhang E, Liu H, Yang D, Chen X, Lu M, Xu Y.

PLoS One. 2011;6(7):e22524. doi: 10.1371/journal.pone.0022524. Epub 2011 Jul 22.

13.

Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice.

Wang S, Qiu L, Liu G, Li Y, Zhang X, Jin W, Gao GF, Kong X, Meng S.

Vaccine. 2011 Aug 26;29(37):6342-51. doi: 10.1016/j.vaccine.2011.05.008. Epub 2011 May 19.

PMID:
21600951
14.

Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B.

Lebossé F, Testoni B, Fresquet J, Facchetti F, Galmozzi E, Fournier M, Hervieu V, Berthillon P, Berby F, Bordes I, Durantel D, Levrero M, Lampertico P, Zoulim F.

J Hepatol. 2017 May;66(5):897-909. doi: 10.1016/j.jhep.2016.12.024. Epub 2016 Dec 30.

PMID:
28043874
15.

Specificity of humoral and cellular immune response against recombinant particles of nucleocapsid protein of human hepatitis B virus in rabbits.

Isaguliants MG, Kadoshnikov YP, Kalinina TI, Smirnov VD, Wahren B.

Biochemistry (Mosc). 1998 May;63(5):551-8.

PMID:
9632891
16.
17.

New enzyme immunoassay for detection of hepatitis B virus core antigen (HBcAg) and relation between levels of HBcAg and HBV DNA.

Kimura T, Rokuhara A, Matsumoto A, Yagi S, Tanaka E, Kiyosawa K, Maki N.

J Clin Microbiol. 2003 May;41(5):1901-6.

18.

Immunopathology on hepatocyte expression of HBV surface, core, and x antigens in chronic hepatitis B: clinical and virological correlation.

Chu CM, Shyu WC, Liaw YF.

Dig Dis Sci. 2010 Feb;55(2):446-51. doi: 10.1007/s10620-009-0895-0. Epub 2009 Aug 13.

PMID:
19680810
19.

Antibody-dependent and antibody-independent uptake of HBsAg across human leucocyte subsets is similar between individuals with chronic hepatitis B virus infection and healthy donors.

Tharinger H, Rebbapragada I, Samuel D, Novikov N, Nguyen MH, Jordan R, Frey CR, Pflanz S.

J Viral Hepat. 2017 Jun;24(6):506-513. doi: 10.1111/jvh.12667. Epub 2017 Feb 1.

PMID:
28012213
20.

HBcAg-pulsed dendritic cell vaccine induces Th1 polarization and production of hepatitis B virus-specific cytotoxic T lymphocytes.

Chen W, Shi M, Shi F, Mao Y, Tang Z, Zhang B, Zhang H, Chen L, Chen L, Xin S, Wang FS.

Hepatol Res. 2009 Apr;39(4):355-65. doi: 10.1111/j.1872-034X.2008.00468.x.

PMID:
19889049

Supplemental Content

Support Center